Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
